Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting ...

Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

His first case: the mysterious closure of Yadu’s Pav Bhaji, followed by an epic farm adventure with Swapna Di. In the ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...